Michael A. Postow, MD

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss ongoing research to watch in advanced melanoma.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss where RP1 plus nivolumab could fit in the advanced melanoma treatment paradigm.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, break down data from the IGNYTE trial of RP1 plus nivolumab in advanced melanoma after PD-1 inhibition.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, dive into research behind oncolytic viruses in advanced melanoma.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss the role of interventional radiologists in melanoma management.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss unmet needs in advanced melanoma after checkpoint inhibition.

Michael A. Postow, MD, discusses the potential role for triplet regimens in melanoma management.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of encorafenib plus binimetinib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combinations of regimens for patients with high-risk melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the advancements that have recently taken place in immunotherapy in the field of melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements seen with immunotherapy in the treatment of patients with melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape in melanoma.